Other Desmoid Tumor Research Worldwide (orig) - Desmoid Tumor Research Foundation
Menu

Posters, Abstracts & Presentations

DTRF encourages researchers to send us summaries about their work with desmoid tumors. Those interested should contact us with this information. View DTRF-funded studies here.

2017 DTRF Research Workshop Abstracts and Presentations

  • David Kirsch, MD, PhD, Barbara Levine University Professor and Vice Chair for Basic & Translational Research, Department of Radiation Oncology Professor, Department of Pharmacology & Cancer Biology, Duke University. 

 

  • Tom van Cann, MD, Medical Oncologist, KU Leuven.
    • “Systemic treatment preferences for patients with advanced desmoid-type fibromatosis in Europe.”  Abstract

 

  • Milea J.M. Timbergen, MD, PhD candidate, Erasmus Medical Center.
    • “Results of the interim analysis of the Dutch GRAFITI study.”  Abstract  |  Presentation

 

  • Breelyn Wilky, MD, Assistant Professor in Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center.
    • “Mutation phenotypes and their responses to chemotherapy.”  

 

  • Chiara Colombo MD, Surgical Oncology, Fondazione IRCCS- Instituto Tumori di Milano.
    • β -catenin in Desmoid-Type Fibromatosis: deep insights on the role of T41A and S45F mutations on protein structure and gene expression.”  

 

  • Danielle Braggio, PhDPost-Doctoral Researcher, Ohio State University.
    • “Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.”  Abstract  |  Presentation

 

  • Yoshihiro Nishida, MD, PhD, Associate Professor, Nagoya University Graduate School of Medicine.
    • “Effects of mechanical forces on the cell behavior of desmoid-type fibromatosis.”  Abstract

 

  • Kris Vleminckx, PhD, Professor, Department of Molecular Biomedical Research Unit of Developmental Biology VIB, Ghent University.
    • “Therapeutic target identification in a Xenopus model for desmoid tumor formation – an update.”  Abstract

 

  • Gerlinde Wernig, MD, Assistant Professor of Pathology, Stanford University.
    • “Unifying mechanism of different fibrotic diseases.”  

 

  • Sant Chawla, MD, FRACP, Medical Director, Sarcoma Oncology Research Center.
    • “Designing new clinical trials in desmoid tumor.”  Presentation

 

  • Steve Horrigan, PhD, Chief Scientific Officer, Beta Cat Pharmaceuticals
    • “Tegavivint (BC2059) – A new way of attacking beta-catenin driven disease.”

 

  • Danielle Braggio, PhD, Post-Doctoral Researcher, Ohio State University
    • “Tegavivint (BC2059) studies in desmoid cell lines.”

 

  • Benjamin Alman, MD, Professor and Chair, Department of Orthopedic Surgery, Duke University.
    • “Tegavivint (BC2059) studies in Apc(+)/Apc(1638N) genetic mouse model of aggressive fibromatosis.”  

 

  • Casey Cunningham, MD, Chief Medical Officer, Beta Cat Pharmaceuticals.
    • Synopsis of a Planned Phase 1/2 Study of Tegavivant (BC2059) in desmoid tumors.”  Abstract

 

  • Benjamin Alman, MD, Professor and Chair, Department of Orthopedic Surgery, Duke University.
    • “Introduction and report on Collaboration for a Cure project.”  Presentation

 

  • Kelly Mercier, PhD, Research Scientist in Metabolomics, RTI International.
    • “A metabolomics pilot study on desmoid tumors and novel drug candidates.”  Abstract  |  Presentation

 

  • Gary Schwartz, MD, Chief, Division of Hematology/Oncology, Columbia University.
    • A systems biology approach to the identification of new treatments for patients with soft tissue sarcomas including desmoid tumors.”  Abstract  |  Presentation

 

  • Aaron Weiss, DO, Assistant Clinical Professor of Pediatrics, Maine Medical Center.

 

  • Kelly Mercier, PhD, Research Scientist in Metabolomics, RTI International.
    • “DTRF Natural History Study and patient registry launch and update.”  Abstract  |  Presentation

2017 DTRF Patient Meeting Abstracts and Presentations

  • R. Lor Randall, MD, FACS, Director of Sarcoma Services, Huntsman Cancer Institute, University of Utah, “Desmoid tumors:  the nonmalignant malignancy.” Presentation

 

  • Victor M. Villalobos, MD, PhD, Assistant Professor of Medicine, Director, Sarcoma Medical Oncology, University of Colorado – Denver, “Desmoid tumor trial using a gamma secretase inhibitor PF-03084014.” Presentation

 

  • Lara Sullivan, MD, MBA“Update on clinical trial for PF-03084014 GSI compound.” 

 

  • Benjamin Alman, MD, Professor and Chair, Department of Orthopedic Surgery, Duke University, “Collaboration for a Cure: what we’ve learned so far.” Presentation

 

  • Jonathan Northrup, CEO, and Casey Cunningham, CMO, Beta Cat Pharmaceuticals, “Upcoming trial of Tegavivant (BC2059) in desmoid tumors.” Presentation

Beta Cat Pharmaceuticals will speak about the upcoming trial of Tegavivint, a new drug targeting desmoid malignancies.  Tegavivint is the first drug that directly interferes with beta-catenin stabilization.  Targeting beta-catenin in this way may hold promise for desmoid sufferers, as the science that has evolved shows that desmoid tumors are due to mutations in the beta-catenin gene, CTNNB1, which cause improper degradation of beta-catenin.  Tegavivint has shown promise indirectly, specifically and potently reversing this condition in preclinical studies and is planned for early clinical study at the end of this year.

  • Kelly Mercier, PhD, Research Scientist in Metabolomics, RTI International, “The DTRF Desmoid Tumor Patient Registry.” Presentation

 

  • Michael Cassidy, MD, Fellow, Complex Surgical Oncology, Memorial Sloan Kettering Cancer Center, “MRI characteristic predictive of progression.” Presentation

 

  • Rachel Sitta, Patient advocate.

 

  • Breelyn Wilky, MD, Assistant Professor in Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, “Mutation phenotypes and their responses to chemotherapy.”

 

  • Lauren Peters, RD, CSO, LDN, Fox Chase Cancer Center & Jeanes Hospital, “Nourished: Is Your Food Fueling You?”

 

  • Barbara Van Hare, Director of Foundation Partnerships, The Rare Cancer Research Foundation, “The importance of tissue donation and Pattern.org.” Presentation

 

  • Bernd Kasper, MD, PhD, Professor, Mannheim University Medical Center, Interdisciplinary Tumor Center, Sarcoma Unit, “Update on the Management of Sporadic Desmoid-type Fibromatosis: A European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and EORTC/Soft Tissue and Bone Sarcoma Group (STBSG).”

 

Miscellaneous

Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF- 03084014, an Oral Gamma Secretase Inhibitor, Victor Manuel Villalobos, MD, PhD

 

An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)

Abstract: Desmoid-type fibromatosis (DF) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals’ AND patients’ expertise following a roundtable meeting bringing together sarcoma experts from the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) with patients and patient advocates from Sarcoma Patients EuroNet (SPAEN). In this paper, we focus on new findings regarding the prognostic value of mutational analysis in DF patients and new systemic treatment options.  

 

“Biology & Treatment of Aggressive Fibromatosis or Desmoid Tumor”, Keith Skubitz, MD  

 

Childhood Soft Tissue Sarcoma Treatment (PDQ®): Health Professional Version This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood soft tissue sarcoma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).  

 

Abdominal Wall Reconstruction Abdominal wall reconstruction has become a frequently used term to describe hernia repairs that try to recreate the abdominal wall and restore function and structure. Although there has been no true definition of a functional abdominal wall, many surgeons believe this involves the closure of the fascia at the midline often with reinforcement using mesh prosthetics. The integrity of the abdominal wall is vital as it serves to protect the internal organs, supports the spine and helps maintain an upright posture. Several tumors can occur on the abdominal wall, and the most common are desmoid tumors. These lesions even though histologically benign, often are very locally invasive. Treatment of desmoids often requires full thickness abdominal wall excision. Despite this, local recurrence rates are nearly 40% to 50%. Most of these recurrences occur within the first 24 months after surgery. In some cases, adjuvant radiation therapy is recommended especially when the margins are not clear. Management of malignant lesions of the abdominal wall requires aggressive resection of the subcutaneous tissues and skin, as well as any involved muscle. Sarcomas are the most common tumors of the abdominal wall and require aggressive resection, followed by radiotherapy. There may also be some intraabdominal wall tumors either via hematogenous or contiguous spread that require resection. Reconstruction of the abdominal wall in these cases is usually directed by the extent of resection and the possibility of further surgical intervention.

2016 ASCO Annual Meeting

Abstracts

  • Geraldine Helen O’Sullivan Coyne, Shivaani Kummar, Khanh Tu Do, Peter L. Choyke, Baris Turkbey, Eric Polley, Yvonne Horneffer, Lamin Juwara, Rasa J Vilimas, Robert S. Meehan, Lee J. Helman, James H. Doroshow, Alice P. Chen; Early Clinical Trials Development Program, DCTD, National Cancer Institute at the National Institutes of Health, Bethesda, MD; National Cancer Institute, Bethesda, MD; Dana-Farber Cancer Center/Brigham and Women’s Hospital, Boston, MA; National Cancer Institute at the National Institutes of Health, Bethesda, MD; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; Mayo Clinic, Rochester, MN; Leidos BioMedical Research, Inc, Bethesda, MD; Early Clinical Trials Development Program, DCTD, NCI, Bethesda, MD; Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD; Early Clinical Trials Development Program, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.

  • Angela Pang, Daniela Venancio Gouveia Macedo, Mariana Carbini, Robert G. Maki; Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY; Oncology Division, Hospital de Santa Maria – CHLN, Lisbon, Portugal; Tisch Cancer Insitute, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY

Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients.”

  • Olivier Mir, Chahinez Rahal, Françoise Rimareix, Julien Adam, Philippe Terrier, Julien Domont, Sarah Dumont, Arslane Skander Rahal, Andrea Cavalcanti, Isabelle Sourrouille, Nicolas Leymarie, Charles Court, Gilles Missenard, Leila Haddag-Miliani, Charles Honoré, Axel Le Cesne; Gustave Roussy Cancer Campus, Department of Medical Oncology, Villejuif, France; Gustave Roussy Cancer Campus, Villejuif, France; Department of Biopathology, Gustave Roussy Cancer Center, Villejuif, France

Efficacy of oral vinorelbine in advanced/progressive desmoid tumours: An updated retrospective study in 50 patients.

  • Nuria Kotecki, Armelle Renaud, Mariem Ben Haj Amor, Anne-Sophie Thomassin Defachelles, Thomas Ryckewaert, Vincent Gamblin, Yves Marie Robin, Sophie Taieb, Nicolas Penel; Oscar Lambret Center, Lille, France; Centre Oscar Lambret, Lille, France

Is symptom worsening (SW) associated with RECIST response in patients (pts) with desmoid tumors (DT)?

  • Rodrigo Ramella Munhoz, Robert A Lefkowitz, Deborah Kuk, Mark Andrew Dickson, Sandra P. D’Angelo, Mary Louise Keohan, Ping Chi, Aimee Marie Crago, Robert G. Maki, Gary K. Schwartz, Li-Xuan Qin, William D. Tap, Mrinal M. Gounder; Hospital Sírio Libanês, São Paulo, Brazil; Memorial Sloan Kettering Cancer Center, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY; Columbia University Medical Center – New York Presbyterian Hospital, New York, NY

Efficacy of sorafenib in patients with desmoid-type fibromatosis.

  • Sarmen Sarkissian, John P. Fruehauf; University of California, Irvine, Orange, CA; UCI Comprehensive Cancer Center, Orange, CA

Pazopanib and taxane combinations for metastatic or recurrent soft tissue sarcoma: A retrospective case series.

Posters

  • Rodrigo Ramella Munhoz, Robert A Lefkowitz, Deborah Kuk, Mark Andrew Dickson, Sandra P. D’Angelo, Mary Louise Keohan, Ping Chi, Aimee Marie Crago, Robert G. Maki, Gary K. Schwartz, Li-Xuan Qin, William D. Tap, Mrinal M. Gounder; Hospital Sírio Libanês, São Paulo, Brazil; Memorial Sloan Kettering Cancer Center, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY; Columbia University Medical Center – New York Presbyterian Hospital, New York, NY

Efficacy of sorafenib in patients with desmoid-type fibromatosis.”

  • Geraldine Helen O’Sullivan Coyne, Shivaani Kummar, Khanh Tu Do, Peter L. Choyke, Baris Turkbey, Eric Polley, Yvonne Horneffer, Lamin Juwara, Rasa J Vilimas, Robert S. Meehan, Lee J. Helman, James H. Doroshow, Alice P. Chen; Early Clinical Trials Development Program, DCTD, National Cancer Institute at the National Institutes of Health, Bethesda, MD; National Cancer Institute, Bethesda, MD; Dana-Farber Cancer Center/Brigham and Women’s Hospital, Boston, MA; National Cancer Institute at the National Institutes of Health, Bethesda, MD; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; Mayo Clinic, Rochester, MN; Leidos BioMedical Research, Inc, Bethesda, MD; Early Clinical Trials Development Program, DCTD, NCI, Bethesda, MD; Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD; Division of Cancer Treatment and Diagnosis, NCI, NIH, Bethesda, MD; Early Clinical Trials Development Program, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Activity of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.

2016 DTRF Research Workshop Abstracts & Presentations

Benjamin Alman, MD, Department Chair, Orthopedic Surgery, Duke University, “Introduction and Report on Collaboration for a Cure project.”   Kris Vleminckx, PhD, Professor of Developmental Biology, Ghent University

  • “Identifying targets for therapy in a novel genetic Xenopus model for desmoid tumor formation.”  Abstract

Stephen Horrigan, PhD, Chief Scientific Officer, BetaCat Pharmaceuticals

  • “Tegatrabetan (BC-2059) – A new approach to targeting beta catenin and Wnt activation.”  Abstract

Danielle Braggio, PhD, Post-Doctoral Researcher, Ohio State University

  • “Initial studies of Tegatrabetan (BC-2059) in desmoid tumor cell strains.”  Abstract

Mrinal Gounder, MD, Assistant Professor and Medical Oncologist, Memorial Sloan Kettering Cancer Center, “Development of PRO tool in desmoid tumors.”   Steven Attia, DO, Assistant Professor of Oncology, Mayo Clinic

  • “A model for international, multi-institutional, multi-disciplinary sarcoma videoconferencing.”  Abstract

Nicholas Penel, MD, PhD, Medical Oncology, Centre Oscar Lambret

  •  “The French Patient Registry Project.”  Abstract

Danique van Broekhoven, MD, Surgical Oncology, Erasmus MC

  • “Outcome of non-surgical management of extra-abdominal and abdominal desmoid-type fibromatosis: a population based study.”  Abstract

Matt van de Rijn, MD, PhD, Professor, Department of Pathology, Stanford University Medical Center, “Gene expression profiling of desmoid tumors.”   Danielle Braggio, PhD, Post-Doctoral Researcher, Ohio State University

  • “Investigation of antitumor effects of sorafenib on desmoid tumors.”  Abstract

Lara Sullivan, MD, MBA, Vice President, Pfizer CURES, Pfizer, Inc., “Update on clinical trials on Pfizer compound/ a potential new treatment.”   Peter Hohenberger, MD, Mannheim University Medical Center

  • “An analysis of incidence and significance of trauma prior to desmoid tumor formation.”  Abstract

Nancy Cho, MD, Assistant Professor of Surgery, Harvard Medical School

  • “Targeting hyaluronic acid in desmoid tumors.”   Abstract

Chiara Colombo, MD, Surgical Oncology, Instituto Tumori di Milano

  • “Whole Exome Sequencing in patients under Wait & See (W&S): a preliminary analysis.”  Abstract

Daniela Segat, PhD, Senior Researcher, ”Mauro Baschirotto” Institute for Rare Diseases – B.I.R.D. Foundation,

  • “In vitro studies of the microenvironmental factors responsible of the proliferation and aggressiveness of desmoid tumor cells.”  Abstract  |  Presentation

2016 CTOS Meeting

Abstract

  • N.Kotecki, A.Renaud, M.Ben Haj Amor, A.Thomassin Defachelles, T.Ryckewaert, V.Gamblin, Y.Robin, S.Taieb, N.Penel

“Is symptom worsening (SW) associated with RECIST response in patients (pts) with desmoid tumors (DT)?”

  • Dumnoensun Pruksakorn, Olarn Arpornchayanon, Areerak Phanphaisarn, Saratwadee Lorsomradee, Natthapong Kosachunhanun, Pimpis Teyakasem, Jongkolnee Settakorn5

“The safety and result of intratumoral steroid injection for aggressive fibromatosis.”

Paper

  • Bernd Kasper, Viktor Gruenwald, Peter Reichardt, Sebastian Bauer, Geraldine Rauch, Ronald Limprecht, Michaela Sommer, Antonia Dimitrakopoulou-Strauss, Lothar Pilz, Florian Haller, Peter Hohenberger

“Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).”

Presentation

  • Danielle Braggio, Abbie Zewdu, Gonzalo Lopez, Kara Batte, Lucia Casadei, David Koller, Raphael Pollock, Dina Lev

“MAPK/ERK Pathway And Inhibits Tumor Growth By Inducing Different Death Pathways In Desmoid Tumor Cell Strains.”

  • Victor M. Villalobos, M.D., Ph.D., Assistant Professor, Director, Sarcoma Medical Oncology/Division of Medical Oncology

Desmoid tumor trial using a gamma secretase inhibitor PF-03084014.”

2016 DTRF Patient Meeting Abstracts & Presentations

Raffi Avedian, MD, The Stanford University Medical Center.

  • “Magnetic resonance guided high intensity focused ultrasound: a novel noninvasive technique to treat soft tissue tumors of the extremity.”  Abstract

Geraldine O’Sullivan Coyne, MD, PhD, NCI- NIH.

  • “NCI’s Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis.”  Abstract

Benjamin Alman, MD, Duke University.

  • “Collaboration for a Cure: what we’ve learned so far.”  Abstract

Kris Vleminckx, PhD, Ghent University.

  • “Fishing for New Therapeutic Targets in the Frog Pond.”

Raphael E. Pollock, MD, PhD, Ohio State University Comprehensive Cancer Center. 

  • “Understanding the S45F and T41A mutations in desmoid tumors. What is their significance?”  Abstract  |  Presentation

Kelly Mercier, PhD, RTI International.

Sunil Sharma, MD, University of Utah School of Medicine, Expert in Oncology Drug Development.

Ian Bier, ND, PhD, LAc, FABNO, Human Nature Natural Health.

  • “Naturopathic Oncology: What is it, and how can it help?”  Presentation

Secili DeStefano, PT, DPT, OCS, Bodies in Motion Physical Therapy.

Presentation: “Optimizing Movement to Improve the Human Experience.”

Miscellaneous

Dr. Bernd Kasper of Mannheim University Medical Center

  • Brief video followup on “Clinical and translational research results of a phase II study evaluating imatinib to induce progression arrest in RECIST progressive desmoid tumors- A study of the German Interdisciplinary Sarcoma Group (GISG- 01)”

2015 CTOS Meeting

Jacob Bickels, MD, Orthopaedic Oncology, Sourasky Medical Center, Israel

Poster: “Aminolevulinic acid photoablation of fibrotic soft-tissue tumors: preliminary report of 24 patients.”

Chiara Colombo, MD, Surgical Oncology, Fondazione IRCCS Istituto Tumori di Milano

Poster: “Gene expression analysis identifies a potential role of immune system in CTNNB1 mutated desmoid tumors.”

Amanda Kirane, MD, Surgery, Memorial Sloan Kettering Cancer Center

Poster: “Progression of desmoid-type fibromatosis during active observation is associated with tumor size.”

Poster: “Molecular characterization of desmoid tumors.”

2015 DTRF Patient Meeting Presentations

Benjamin Alman, MD, Duke University

  • “Collaboration for a cure: What we’ve learned so far.”  Presentation

Aimee Crago, MD, PhD, Memorial Sloan Kettering Cancer Center

  • “Personalizing management of desmoid tumors.”  Presentation

Kishore Iyer, FRCS, FACS, Mount Sinai Hospital

  • “Challenging Conventional Limits of Inoperability in Abdominal Desmoids and Sarcomas.”  Presentation

Robert Lefkowitz, MD, Memorial Sloan Kettering Cancer Center

Bernd Kasper, MD, PhD, Mannheim University Medical Center

Jean Paty, PhD, Principle, Advisory Services, Quintiles

2015 DTRF Research Workshop Abstracts & Presentations

Mushriq Al-Jazrawe, University of Toronto

Radhika Atit, PhD, Case Western University

  • “Sustained β-catenin activation in dermal fibroblasts promotes fibrosis by regulating cell proliferation and extracellular matrix protein-coding genes.”  Presentation

Benjamin Alman, MD, Duke University

  • “From the bedside to the bench and the back again.”  Presentation

Danielle Braggio, PhD, Ohio State University

  • “Reactivation of apoptosis as a potential therapeutic target for desmoid tumors with CTNNB1 S45F mutation.”  Abstract  |  Presentation
  • “Targeting the notch pathway: a potential therapeutic approach for desmoid tumors.”  Abstract
  • “Desmoid Tumors Harboring S45F B-catenin Mutation are Highly Resistant to Apoptosis.”  Presentation

Alice Chen, MD, National Institutes of Health/ National Cancer Institute

  • “A Phase II trial of PF-03084014 in adults with Desmoid tumors/Aggressive Fibromatosis.”  Abstract  |  Presentation

Meredith Chuk, MD, Food and Drug Administration

  • “FDA Draft Guidance- Rare Diseases: Common Issues in Drug Development.”  Presentation

Aimee Crago, MD, PhD, Memorial Sloan Kettering Cancer Center

  • “Oncogenic effects of activated beta-catenin in desmoid fibromatosis.”  Abstract
  • “Whole Exome Sequencing and Integrated Genomic Analysis of ‘Wild-Type’ Desmoids Identifies Potential Drivers of Tumor Initiation.”  Abstract

Alessandro Datti, PhD, SMART Laboratory for High Throughput Screening Programs

  • “Introduction to drug repositioning towards novel therapeutics for desmoid tumors.”  Presentation

Mrinal Gounder, MD, Memorial Sloan Kettering Cancer Center

  • “Notch inhibition in desmoids: Sure it works in practice, but does it work in theory?”  Article

Katherine Hartley, MD, Vanderbilt University

  • “Image-guided cryoablation for desmoid tumors: successes, challenges and lessons learned.”  Poster
  • “16α-[18F]-fluoro-17ß-estradiol (18F-FES) PET/CT Imaging of Estrogen Receptor Activity in Desmoid Tumors.”  Poster

Bernd Kasper, MD, PhD, Mannheim University Medical Center

  • “Clinical and translational research results of a phase II study evaluating imatinib to induce progression arrest in RECIST progressive desmoid tumors- A study of the German Interdisciplinary Sarcoma Group (GISG- 01).”  Presentation

Kelly Mercier, PhD, RTI International

  • “Metabolomics: Towards a Better Understanding of Desmoid Tumors.”  Abstract  |  Presentation

Yoshihiro Nishida, MD, PhD, Nagoya University

  • “Planned simple resection for selected patients with extra-peritoneal desmoid tumors.”  Abstract  |  Presentation

Raphael Pollock, MD, PhD, Ohio State University

  • “Targeting the notch pathway: A potential therapeutic approach to desmoid tumors.”  Article

Ty Subhawong, University of Miami Miller School of Medicine

  • “MRI Features of Response in Systemic Therapy for Aggressive Fibromatosis.”  Presentation

2013 SPAEN Conference

Sylvie Bonvalot, MD, PhD, Institut de Cancerologie- Gustave Roussy Presentation:  “Management of desmoids”   Rick Haas, Netherlands Cancer Institute- Amsterdam Presentation: “The role of radiotherapy in desmoids”   Bernd Kasper, MD, PhD, Mannheim University Medical Center Presentation: “Update on systemic treatment options and clinical trials in desmoids”   Daniela Segat, PhD, B.I.R.D Foundation Presentation:  “Unraveling the desmoid-type fibromatosis at the cellular level: GSK- 3beta, a new piece of the puzzle”

Miscellaneous

Sumer Sethi, Sumer’s Radiology Blog, 2009- CTs versus MRIs on desmoid tumors

  TOP